Research Topics
Species | R J KreitmanSummaryAffiliation: National Institutes of Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicitySookhee Bang
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, 37 Convent Drive, Bethesda, MD 20892, USA
Clin Cancer Res 11:1545-50. 2005..Because HA22 (R490A) has increased antitumor activity without increased animal toxicity, immunotoxins with this mutation are candidates for clinical development...
Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemiaRobert J Kreitman
National Cancer Institute, National Institutesof Health, Bethesda, USA
J Clin Oncol 30:1822-8. 2012..To conduct a phase I dose-escalation trial assessing safety and response of recombinant immunotoxin moxetumomab pasudotox (CAT-8015, HA22) in chemotherapy-resistant hairy cell leukemia (HCL)...- Recombinant fusion toxins for cancer treatmentRobert J Kreitman
Clinical Immunotherapy Section, Laboratory of Molecular Biology, Division of Cancer Biology, National Cancer Institute/National Institutes of Health, 9000 Rockville Pike, Building 37, Room 5124b, Bethesda, MD 20892-4255, USA
Expert Opin Biol Ther 2:785-91. 2002 - Immunotoxins in the treatment of hematologic malignanciesRobert J Kreitman
Clinical Immunotherapy Section, Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 37, Room 5124b, Bethesda, MD 20892 4255, USA
Curr Drug Targets 7:1301-11. 2006..Several other recombinant immunotoxins are undergoing preclinical development for other target antigens expressed on hematologic malignancies... - Immunotoxins for targeted cancer therapyRobert J Kreitman
Clinical Immunotherapy Section, Laboratory of Molecular Biology, Centers for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 37, Room 5124b, Bethesda, MD 20892 4255, USA
AAPS J 8:E532-51. 2006..Refinement of existing immunotoxins and development of new immunotoxins are underway to improve the treatment of cancer... - BL22 and lymphoid malignanciesRobert J Kreitman
Centers for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 37, Room 5124b, Bethesda, MD 20892 4255, USA
Best Pract Res Clin Haematol 19:685-99. 2006..Already under way are a phase-II trial in HCL and phase-I trials in chronic lymphocytic leukemia (CLL) and acute lymphocytic leukemia (ALL) administering BL22 in a modified protocol in an effort to prevent HUS... - Immunotoxins in the treatment of refractory hairy cell leukemiaRobert J Kreitman
Clinical Immunotherapy Section, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 37, Room 5124b, Bethesda, MD 20892 4255, USA
Hematol Oncol Clin North Am 20:1137-51, viii. 2006..Both agents, termed LMB-2 and BL22, respectively, have been tested in patients who have HCL after failure of purine analogs and other therapies; major responses have been achieved in most patients... - Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignanciesRobert J Kreitman
Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bldg 5124b, 9000 Rockville Pike, Bethesda, MD 20892, USA
J Clin Oncol 23:6719-29. 2005..To conduct a phase I trial of recombinant immunotoxin BL22, an anti-CD22 Fv fragment fused to truncated Pseudomonas exotoxin... - Recombinant toxins for the treatment of cancerRobert J Kreitman
Division of Cancer Biology, National Institutes of Health, 9000 Rockville, Bethesda, MD 20892, USA
Curr Opin Mol Ther 5:44-51. 2003..The number of approved recombinant toxins for the treatment of cancer is expected to increase in the coming years... - Immunobiological treatments of hairy-cell leukaemiaRobert J Kreitman
Laboratory of Molecular Biology, Centers for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 37, Room 5106, Bethesda, MD 20892 4255, USA
Best Pract Res Clin Haematol 16:117-33. 2003..The unlabelled mAb rituximab has also been reported to induce responses in the majority of HCL patients treated, and several CRs have been observed... - Confirmation and prevention of targeted toxicity by a recombinant fusion toxinRobert J Kreitman
Clinical Immunotherapy Section, Laboratory of Molecular Biology, Centers for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892-4255, USA
Mol Cancer Ther 3:1691-2. 2004 - Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignanciesRobert J Kreitman
Clinical Immunotherapy Section, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
BioDrugs 23:1-13. 2009..The most successful application of recombinant immunotoxins today is in hairy cell leukemia, where BL22 has induced complete remissions in most patients who were previously treated with optimal chemotherapy... - Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1PRobert J Kreitman
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 4264, USA
Clin Cancer Res 15:5274-9. 2009..To conduct a phase I trial of recombinant immunotoxin SS1P given by continuous infusion in chemoresistant solid tumors expressing mesothelin... - Immunotoxins in cancer therapyR J Kreitman
Laboratory of Molecular Biology, Division of Cancer Biology, National Cancer Institute, National Institutes of Health, 37 4B27, 9000 Rockville Pike, 4255 Bethesda, MD 20892, USA
Curr Opin Immunol 11:570-8. 1999..Efforts are underway to obviate impediments to clinical efficacy, including immunogenicity and toxicity to normal tissues. Immunotoxins are now being developed to new antigens for the treatment of cancer... - Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotoxRobert J Kreitman
Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, Maryland, USA
Clin Cancer Res 17:6398-405. 2011..Moreover, protein engineering is being used to increase its activity, decrease nonspecific side effects, and remove B-cell epitopes... - ImmunotoxinsR J Kreitman
Laboratory of Molecular Biology, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, 37 4B27, 37 Convent Drive Msc 4255 Bethesda, MD 20892, USA
Expert Opin Pharmacother 1:1117-29. 2000..Some of these molecules may enter clinical practice in the future as targeted therapy, which is a modality distinct from those of chemotherapy, surgery and radiation therapy... 
Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemiaRobert J Kreitman
Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Leuk Lymphoma 52:82-6. 2011..In separate randomized trials, rituximab is undergoing phase II testing with cladribine for early HCL and with bendamustine or pentostatin for multiply relapsed HCL...- Recombinant immunotoxins for the treatment of haematological malignanciesRobert J Kreitman
Clinical Immunotherapy Section, Laboratory of Molecular Biology, Centers for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 37, Room 5124b, Bethesda, MD 20892 4255, USA
Expert Opin Biol Ther 4:1115-28. 2004..One of these molecules, BL22, targets CD22 on hairy-cell leukaemia and has enabled patients to achieve complete remissions despite previous treatment and resistance to chemotherapy... - Approach to the patient after relapse of hairy cell leukemiaRobert J Kreitman
Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Leuk Lymphoma 50:32-7. 2009..An improved high-affinity version of BL22, termed HA22, is currently undergoing phase I testing... - Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemiaR J Kreitman
Laboratory of Molecular Biology, National Cancer Institute, Bethesda, MD 20892, USA
N Engl J Med 345:241-7. 2001..We tested the safety and efficacy of an immunotoxin directed against a surface antigen that is strongly expressed by leukemic hairy cells... - Chimeric fusion proteins--Pseudomonas exotoxin-basedR J Kreitman
National Cancer Institute, NIH, Clinical Immunotherapy Section, Laboratory of Molecular Biology, Division of Cancer Biology, 9000 Rockville Pike, Building 37, Room 4B 27, Bethesda, MD 20892 4255, USA
Curr Opin Investig Drugs 2:1282-93. 2001..This review will focus on several agents containing truncated Pseudomonas exotoxin, which are undergoing preclinical and clinical development... - Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemiaRobert J Kreitman
Laboratory of Molecular Biology, Laboratory of Clinical Pathology, and Medicine Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA
J Clin Oncol 27:2983-90. 2009..To conduct a phase II trial in chemoresistant hairy cell leukemia (HCL) with BL22, a recombinant anti-CD22 immunotoxin which showed phase I activity in HCL... - Recombinant immunotoxins for the treatment of chemoresistant hematologic malignanciesRobert J Kreitman
Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, 37 5124b, 9000 Rockville Pike, Bethesda, MD 20892, USA
Curr Pharm Des 15:2652-64. 2009..HA22, an improved version of BL22 with higher affinity to CD22, is now undergoing phase I testing in HCL, CLL, non-Hodgkin's lymphoma, and pediatric acute lymphoblastic leukemia... - Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytomaR K Puri
Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, NIH, Bethesda, Maryland 20892, USA
Cancer Res 56:5631-7. 1996..We conclude that by localized administration, nontoxic levels of IL4(38-37)-PE38KDEL can be achieved, which may have significant cytotoxic activity against malignant astrocytoma... - Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activityM Onda
Laboratory of Molecular Biology, Division of Basic Sciences, National Cancer Institute, NIH, Bethesda, Maryland 20892-4255, USA
Cancer Res 61:5070-7. 2001..Therefore, lowering the pI of the Fv may be a general approach to diminish the nonspecific toxicity of recombinant immunotoxins and other Fv fusion proteins without losing antitumor activity... - Isolation of new anti-CD30 scFvs from DNA-immunized mice by phage display and biologic activity of recombinant immunotoxins produced by fusion with truncated pseudomonas exotoxinH Rozemuller
Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Int J Cancer 92:861-70. 2001..Our data show that DNA immunization and antibody phage display may be useful in producing new rITs against hematologic malignancies. Published 2001 Wiley-Liss, Inc... - Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicityY Tsutsumi
Laboratory of Molecular Biology, Division of Basic Science, National Cancer Institute, National Institutes of Health, Building 37, Room 4E16, 37 Convent Drive MSC 4255, Bethesda, MD 20892 4255, USA
Proc Natl Acad Sci U S A 97:8548-53. 2000..This was accompanied by a substantial decrease in animal toxicity and immunogenicity. Site-specific PEGylation of recombinant immunotoxins may increase their therapeutic potency in humans... - Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragmentsSatoshi Nagata
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892-4264, USA
Clin Cancer Res 8:2345-55. 2002..Two of these showed good cytotoxic activity to various CD30-positive cell lines. These newly produced immunotoxins should be additionally evaluated for the treatment of CD30-positive lymphomas... - Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patientsMasanori Onda
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Bethesda, MD 20892, USA
J Immunol 177:8822-34. 2006..Our results indicate that a relatively small number of discrete immunogenic sites are associated with PE38, most of which can be eliminated by point mutations... - A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicityJohn E Weldon
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892 4264, USA
Blood 113:3792-800. 2009..We conclude that HA22-LR advances the therapeutic efficacy of HA22 by using an approach that may be applicable to other PE-based immunotoxins... - Immunoglobulin superfamily receptor translocation associated 2 protein on lymphoma cell lines and hairy cell leukemia cells detected by novel monoclonal antibodiesTomoko Ise
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 4264, USA
Clin Cancer Res 11:87-96. 2005..To study the expression of the IRTA2 gene product, we produced monoclonal antibodies (MAbs) specific to IRTA2... - Characterization of T-cell repertoire in hairy cell leukemia patients before and after recombinant immunotoxin BL22 therapyEvgeny Arons
Laboratories of Molecular Biology and Pathology, and Biostatistics and Data Management Section, Centers for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Cancer Immunol Immunother 55:1100-10. 2006.... - SV40 Pseudovirion gene delivery of a toxin to treat human adenocarcinomas in miceC Kimchi-Sarfaty
Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4256, USA
Cancer Gene Ther 13:648-57. 2006..These results indicate that SV40 in vitro packaging is an effective system for cancer gene delivery using two different routes of injection and in combination with chemotherapy... - IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion proteinB H Joshi
Laboratory of Molecular Tumour Biology, Division of Cellular and Gene Therapies, Center for Biologics, Evaluation and Research, Food and Drug Administration, NIH Building 29B, Room 2NN10, 29 Lincoln Dr, Bethesda, Maryland, MD 20892, USA
Br J Cancer 86:285-91. 2002..Further studies are warranted to investigate interleukin-4 receptor expression in primary medulloblastoma tumours and sensitivity to cpIL-4PE in vitro and in vivo... - Expression and targeting of interleukin-4 receptor for primary and advanced ovarian cancer therapyMitomu Kioi
Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
Cancer Res 65:8388-96. 2005..These results indicate that IL-4R-targeted cytotoxin may be a useful agent for the management of patients with ovarian cancer, and further studies need to be done to evaluate its safety, tolerability, and efficacy... - Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2Peter Attia
Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Immunother (1997) 29:208-14. 2006..The short in vivo half-life of LMB-2 makes it an attractive candidate for reducing human T(reg) cells in vivo before the administration of cancer vaccine or cell transfer immunotherapy approaches... - In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxinMitchell Ho
Laboratory of Molecular Biology, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland 20892, USA
J Biol Chem 280:607-17. 2005..Our results demonstrate that germline hot spots but not non-germline hot spots are effective for in vitro antibody affinity maturation... - Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphomaT Ise
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Leukemia 21:169-74. 2007..Because CD307 is present on malignant cells from patients with MM, CLL and MCL, CD307 may be a useful therapeutic target for the treatment of these diseases... - Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivoDaniel J Powell
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
J Immunol 179:4919-28. 2007.... - Immunotoxins in cancer therapyIra Pastan
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 4264, USA
Curr Opin Investig Drugs 3:1089-91. 2002..Unfortunately, most antibodies do not kill cancer cells unless they are armed with a cytotoxic agent, such as a radioisotope, a cytotoxic drug, or a protein toxin. Each of these have advantages and disadvantages... - Immunotoxin treatment of cancerIra Pastan
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Annu Rev Med 58:221-37. 2007..Strategies to overcome these limitations are being pursued... - Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage displayGiuliana Salvatore
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892-4264, USA
Clin Cancer Res 8:995-1002. 2002..The THW mutant had a 5- to 10-fold increase in activity on various CD22-positive cell lines and was up to 50 times more cytotoxic to cells from patients with chronic lymphocytic leukemia and hairy-cell leukemia... - Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in miceDavid Filpula
Enzon Pharmaceuticals, Incorporated, 20 Kingsbridge Road, Piscataway, New Jersey 08854, and Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
Bioconjug Chem 18:773-84. 2007..Since the bioconjugates can also exhibit the attributes of passive targeting via enhanced permeability and retention, this is the first demonstration of a pivotal role of active targeting for immunotoxin bioconjugate efficacy... - Immunotoxin therapy of cancerIra Pastan
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institues of Health, 37 Convent Drive, Bethesda, MD 20892 4264, USA
Nat Rev Cancer 6:559-65. 2006..Results from clinical trials indicate that recombinant immunotoxins and similar agents that are designed to combine antibody selectivity with toxin cell-killing potency will be useful additions to cancer therapy... - Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trialAlan S Wayne
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1104, USA
Clin Cancer Res 16:1894-903. 2010..We conducted the first preclinical and phase I clinical studies of BL22 in that setting... - Localization of mesothelin in epithelial ovarian cancerRaffit Hassan
Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 4264, USA
Appl Immunohistochem Mol Morphol 13:243-7. 2005..Patients whose tumors express mesothelin could be eligible for participation in clinical trials of novel agents targeting mesothelin... - New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISAMasanori Onda
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892-4264, USA
Clin Cancer Res 11:5840-6. 2005.... - Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancersRaffit Hassan
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute and Clinical Center, NIH, Bethesda, Maryland 20892 4264, USA
Clin Cancer Res 13:5144-9. 2007..To determine the toxicities, maximum tolerated dose (MTD) and pharmacokinetics of the recombinant immunotoxin SS1P (anti-mesothelin dsFv-PE38) in patients with mesothelin-expressing cancers... - Toxin-labeled monoclonal antibodiesR J Kreitman
Laboratory of Molecular Biology, Division of Cancer Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Curr Pharm Biotechnol 2:313-25. 2001..New recombinant immunotoxins are currently being engineered and developed to target other hematologic and solid tumor antigens... - VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapyEvgeny Arons
Laboratories of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Blood 114:4687-95. 2009..Response to initial single-agent cladribine therapy is suboptimal; these patients should be considered for alternative approaches, including antibody-related therapy... - Immunoglobulin light chain repertoire in hairy cell leukemiaEvgeny Arons
Laboratories of Molecular Biology and Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 4255, USA
Leuk Res 31:1231-6. 2007..In HCL, we confirm the lack of kappa predominance observed in normal lymphocytes and in chronic lymphocytic leukemia, and note over-representation of several light chain genes... - Soluble CD22 as a tumor marker for hairy cell leukemiaKakushi Matsushita
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20854 4255, USA
Blood 112:2272-7. 2008..Trials are listed on www.cancer.gov as NCT00002765, NCT00021983, NCT00074048, NCT00085085, NCT00337311, and NCT00462189... - PRAME expression in hairy cell leukemiaEvgeny Arons
Laboratories of Molecular Biology and Clinical Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 4255, United States
Leuk Res 32:1400-6. 2008..We conclude that HCL and CLL differ in PRAME overexpression, and that basal normal expression of PRAME may limit its usefulness for following patients with minimal residual CLL or HCL... - Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain geneJustin E Sausville
Laboratory of Pathology, Bldg 10, Room 2N-108, Mail Stop 1500, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Am J Clin Pathol 119:213-7. 2003..FC was adequate in 86 cases (100%), while cpPCR was adequate in 74 cases (86%). FC is superior to cpPCR for detecting minimal residual HCL. It is more sensitive and more specific and permits quantitation of tumor cell number... - Sandwich ELISAs for soluble immunoglobulin superfamily receptor translocation-associated 2 (IRTA2)/FcRH5 (CD307) proteins in human seraTomoko Ise
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Bethesda, MD 20892, USA
Clin Chem Lab Med 44:594-602. 2006..The membrane form is highly expressed on the surface of hairy cell leukemia (HCL) cells from patients. This study aimed to develop immunoassays for soluble IRTA2/FcRH5 proteins in human serum... - Somatic hypermutation and VH gene usage in hairy cell leukaemiaEvgeny Arons
Clinical Immunotherapy Section, Laboratory of Molecular Biology, Centers for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
Br J Haematol 133:504-12. 2006.... - Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reactionEvgeny Arons
Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892-4255, USA
Clin Cancer Res 12:2804-11. 2006..Thus, patient-specific RQ-PCR is the most sensitive test for MRD in HCL patients and could be used to determine maximal response in patients obtaining multiple cycles of nonmyelotoxic biological treatment for this disease... - Multidrug-resistant tumor cells remain sensitive to a recombinant interleukin-4-Pseudomonas exotoxin, except when overexpressing the multidrug resistance protein MRP1Mariska C de Jong
Department of Pathology, VU University Medical Center, 1081 HV Amsterdam, The Netherlands
Clin Cancer Res 9:5009-17. 2003..Still, the results of this study demonstrate that IL-4 toxin effectively kills most MDR tumor cells and, therefore, represents a promising anticancer drug... - Immunotoxin therapy of hematologic malignanciesArthur E Frankel
Wake Forest University School of Medicine, Winston-Salem, NC, USA
Semin Oncol 30:545-57. 2003..Over the next several decades, a growing number of these agents should reach the clinic... - Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotidesThomas Decker
3rd Department of Medicine, Technical University of Munich, Munich, Germany
Blood 99:1320-6. 2002..In summary, immunostimulatory CpG-ODNs efficiently sensitize B-CLL cells to a recombinant immunotoxin by modulation of its target. This new treatment strategy deserves further attention... - Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemiaArthur E Frankel
Wake Forest University Baptist Medical Center, Winston Salem, North Carolina 27157, USA
Clin Cancer Res 8:1004-13. 2002..We tested the safety and efficacy of a diphtheria fusion protein [diphtheria toxin (DT)388 granulocyte-macrophage colony-stimulating factor (GMCSF)] directed against the GMCSF receptor that is strongly expressed by leukemic blasts... - Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenograftsBryce D Beseth
Section of General Thoracic Surgery, University of California, Los Angeles, California 90095-1741, USA
Ann Thorac Surg 78:436-43; discussion 436-43. 2004..CONCLUSIONS: The chimeric protein, IL-4(38-37)-PE38KDEL, has potent antitumor effects against MPM both in vitro and in vivo... - Augmentation of the activity of an immunotoxin, anti-Tac(Fv)-PE40KDEL, in T cell lines infected with human T cell leukemia virus type-INobuhito Ohno
Department of Cancer Chemotherapy, Institute for Cancer Research, Kagoshima University, Japan
Leuk Lymphoma 43:885-8. 2002..CsA was the most potent agent in both the cell lines. Augmentation of the cytotoxic effect of the immunotoxin by these agents, especially CsA, may be useful in the immunotoxin therapy of ATL... - Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trialsJeffrey O Urieto
Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA
Protein Expr Purif 33:123-33. 2004..The synthesis of this protein drug should be useful for production for clinical phase I/II clinical trials and may be suitable for other diphtheria fusion toxins indicated for clinical development... - Immunophenotypic features distinguishing familial chronic lymphocytic leukemia from sporadic chronic lymphocytic leukemiaEjaz Ahmad
Good Samaritan Hospital, Dayton, Ohio, USA
Cytometry B Clin Cytom 74:221-6. 2008..To date no study has been conducted to evaluate and compare patterns of cell surface antigen expression in familial CLL and sporadic CLL... - Taming ricin toxinRobert J Kreitman
Nat Biotechnol 21:372-4. 2003 - CLL immunotoxinsArthur E Frankel
Leuk Res 29:985-6. 2005..A fraction of patients (19%) had CLL cells that were extremely sensitive to the immunotoxin. This novel agent may provide an important new therapeutic for use in the treatment of CLL... - Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxinsThomas Decker
III Medizinische Klinik, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
Blood 103:2718-26. 2004..HA22 was more active than BL22. In conclusion, these immunotoxins induce caspase-mediated apoptosis involving mitochondrial damage. Combination with chemotherapy is expected to improve the efficacy of immunotoxin treatment...